The Ideal Drug for the Treatment of Osteoporosis
The ideal drug for osteoporosis would be one which replaced lost bone and restored its disorganized micro-architecture so that fracture risk was reduced to that of the normal population. It would be free of side effects and sufficiently inexpensive for widespread use. Its beneficial effects on bone would persist for a significant time once therapy was withdrawn, opening the way to intermittent courses of treatment. It should be effective when given by a variety of routes to improve patient acceptance and maintain compliance. Such a drug is not available but several of the currently available compounds fulfill some (but not all) of the requirements and point the way to the future optimization of therapy. There have also been several important recent advances in our understanding of the cell biology of bone which may also lead to the development of better treatment.
KeywordsPlacebo Estrogen Osteoporosis Fluoride Tamoxifen
Unable to display preview. Download preview PDF.
- 1.Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646–50.Google Scholar
- 9.Chestnut CH, McClung MR, Ensrud KE et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med 1995; 99: 44–152.Google Scholar
- 13.Christiansen C, Christensen MS, Transbol I. Bone mass after withdrawal of oestrogen replacement. Lancet 1981 May 9;i:1053–4.Google Scholar